Until recently the application of artificial intelligence (AI) in precision oncology was confined
to activities in drug development and had limited impact on the personalisation of therapy …

Background The number of healthcare interventions described as 'personalised
medicine'(PM) is increasing rapidly. As healthcare systems struggle to decide whether to …

Stem cells can be defined as the cells that have the capacity to both self-renew and give rise
to differentiated cells. Under the right conditions and signals, depending on their origin and …

Improvements in sequencing technology coupled with dramatic declines in the cost of
genome sequencing have led to a proportional growth in the size and number of genetic …

Ever since relevant bioengineering technologies have sufficiently matured to the
platformizable commercialization stage, a slew of money has flocked to the cell and gene …

Gene therapies (GTs) have recently emerged as revolutionary personalized therapeutic
options. Despite their promising potential, challenges such as uncertainty regarding long …

Significant progress has been achieved in human health in the European Union in recent
years. New medicines, vaccines, and treatments have been developed to tackle some of the …

Tissue-engineered products (TEPs) are at the forefront of developmental medicines,
precisely where monoclonal antibodies and recombinant cytokines were 30 years ago …

Background aims Cell and gene therapy products (CGTPs) are anticipated to bring many
benefits for the treatment of conditions with limited or no satisfactory treatment options …

Public participation, transparency and accountability are three of the pillars of good
governance. These pillars become particularly important for innovative, personalised health …